Serum hepcidin levels in cognitively normal older adults with high neocortical amyloid-beta load

Manuscript Number: 

20-0162R2

Author(s): 
Nicholas J. Ashton, Prita R. Asih, Kaj Blennow, Pratishtha Chatterjee, Preeti Dave, Cintia B. Dias, Kathryn Goozee, Abdul Hye, David B. Lovejoy, Ralph N. Martins, Maryam Mohammadi, Steve Pedrini, Tejal Shah, Kaikai Shen, Hamid R. Sohrabi, Kevin Taddei, Henrik Zetterberg

Disclosures

Nicholas J. Ashton

  • Nothing to Disclose

Prita R. Asih

  • Nothing to Disclose

Kaj Blennow

  • Consulting Fees:
    served as a consultant or at advisory boards for Abcam, Axon, Biogen, Lilly, MagQu, Novartis and Roche Diagnostics
    Patents/Royalties
    co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program.

Pratishtha Chatterjee

  • Nothing to Disclose

Preeti Dave

  • Nothing to Disclose

Cintia B. Dias

  • Nothing to Disclose

Kathryn Goozee

  • Nothing to Disclose

Abdul Hye

  • Nothing to Disclose

David B. Lovejoy

  • Nothing to Disclose

Ralph N. Martins

  • Equity:
    Alzhyme Pty Ltd - limited number of shares

Maryam Mohammadi

  • Nothing to Disclose

Steve Pedrini

  • Nothing to Disclose

Tejal Shah

  • Nothing to Disclose

Kaikai Shen

  • Nothing to Disclose

Hamid R. Sohrabi

  • Nothing to Disclose

Kevin Taddei

  • Nothing to Disclose

Henrik Zetterberg

  • Consulting Fees:
    HZ has served at scientific advisory boards for Roche Diagnostics, Samumed, CogRx and Wave.
    Lecture Fees:
    HZ has given lectures in symposia sponsored by Biogen and Alzecure.